Bio-Rad Introduces the BioPlex(TM) 2200

Bio-Rad Introduces the BioPlex(TM) 2200
Revolutionary New Immunoassay Platform Employs Multiplexing Technology 


HERCULES, Calif., July 26  /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc.
(Amex: BIO; BIOb), a multinational manufacturer and distributor of life science
research products and clinical diagnostics, announced the introduction of a
revolutionary new immunoassay platform, the BioPlex(TM) 2200, at the American
Association of Clinical Chemistry Annual Meeting in Los Angeles this week.

The BioPlex(TM) 2200 is the first clinical diagnostics system to offer
multiplexing technology on a fully-automated, fully-integrated random access
platform.  Multiplexing technology is the ability to generate multiple results
from a single patient sample. The BioPlex(TM) 2200 fully automates bead-based
multiplexing, can deliver up to 2200 results per hour, and provides clinical
informatics to aid in diagnosis.

The initial tests on the system will target the Autoimmune diagnostics field.
Bio-Rad is currently a market leader in this area, and the introduction of the
Bioplex(TM) 2200 will further solidify Bio-Rad's commitment to this field. 
Future assays in development are in the areas of serology, infectious disease,
cardiac and toxicology.  Bio-Rad plans to begin U.S. market placements in the
next several months following FDA review.

"We are pleased to be able to provide this revolutionary technology in an
automated and integrated platform," said John Goetz, Vice President of Bio-
Rad's Clinical Diagnostics Group. "We believe it will improve the quality of
testing and aid laboratories in becoming more efficient and cost effective."

Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational
manufacturer and distributor of life science research products and clinical
diagnostics. It is based in Hercules, California, and serves more than 70,000
research and industry customers worldwide through a network of more than 30
wholly owned subsidiary offices.

Various statements made within this press release may constitute "forward-
looking statements" for purposes of the Securities and Exchange Commission's
"safe harbor" provisions under the Private Securities Litigation Reform Act of
1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-
looking statements contained herein involve risks and uncertainties that could
cause results to differ materially from the Company's expectations. 

DATASOURCE: Bio-Rad Laboratories, Inc.



CONTACT:  Christine Tsingos, Vice President and Chief Financial Officer,

or Ron Hutton, Treasurer, both of Bio-Rad Laboratories, Inc.,

[phone], or 



Web site:  http://www.bio-rad.com/ 

Copyright